Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 45, Issue , 2013, Pages 107-116

  Hou, Yue ^a   Zhang, Hongli ^a   Xie, Guanbo ^a   Cao, Xinyue ^a   Zhao, YaNan ^a   Liu, Yang ^a   Mao, Zhihao ^a   Yang, Jingyu ^a   Wu, Chunfu ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Ketamine; Microglia; Neurons; Schizophrenia

Indexed keywords

KETAMINE; MALONALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN NERVE CELL; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; EXPLORATORY BEHAVIOR; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILIZATION; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MAZE TEST; MICROGLIA; MOUSE; NERVE CELL LESION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; RECOGNITION; SCHIZOPHRENIA;

ANALYSIS OF VARIANCE; ANOVA; CENTRAL NERVOUS SYSTEM; CNS; KETAMINE; LEAST SIGNIFICANT DIFFERENCE; LSD; MALONDIALDEHYDE; MDA; MICROGLIA; N-METHYL-D-ASPARTATE; NEURONS; NITRIC OXIDE; NMDA; NO; NOR; NOVEL OBJECT RECOGNITION; PCP; PHENCYCLIDINE; SCHIZOPHRENIA; SOD; SUPEROXIDE DISMUTASE; TNOS; TOTAL NITRIC OXIDE SYNTHASE;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; HIPPOCAMPUS; IMMOBILITY RESPONSE, TONIC; KETAMINE; MALE; MALONDIALDEHYDE; MAZE LEARNING; MICE; MICROGLIA; MOTOR ACTIVITY; NERVE DEGENERATION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PREFRONTAL CORTEX; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIA; SUPEROXIDE DISMUTASE;

EID: 84878946309     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.04.006     Document Type: Article

References (59)

1. Arnold S.E., Trojanowski J.Q., Gur R.E., Blackwell P., Han L.Y., Choi C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch Gen Psychiatry 1998, 55:225-232.
2. Bild W., Hritcu L., Stefanescu C., Ciobica A. Inhibition of central angiotensin II enhances memory function and reduces oxidative stress status in rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 2013, 43:79-88.
3. Bitanihirwe B.K., Woo T.U. Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 2011, 35:878-893.
4. Black J.E., Kodish I.M., Grossman A.W., Klintsova A.Y., Orlovskaya D., Vostrikov V., et al. Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry 2004, 161:742-744.
5. Bošković M., Vovk T., Kores Plesničar B., Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011, 9:301-312.
6. Broadbelt K., Byne W., Jones L.B. Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. Schizophr Res 2002, 58:75-81.
7. Carlsson A., Hansson L.O., Waters N., Carlsson M.L. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 1997, 61:75-94.
8. Chatterjee M., Ganguly S., Srivastava M., Palit G. Effect of 'chronic' versus 'acute' ketamine administration and its 'withdrawal' effect on behavioural alterations in mice: implications for experimental psychosis. Behav Brain Res 2011, 216(1):247-254.
9. Ciobica A., Padurariu M., Dobrin I., Stefanescu C., Dobrin R. Oxidative stress in schizophrenia-focusing on the main markers. Psychiatr Danub 2011, 23:237-245.
10. Cunha G.M., Canas P.M., Melo C.S., Hockemeyer J., Müller C.E., Oliveira C.R., et al. Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp Neurol 2008, 210:776-781.
11. Dakhale G.N., Khanzode S.D., Khanzode S.S., Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 2005, 182:494-498.
12. Duncan G.E., Sheitman B.B., Lieberman J.A. An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 1999, 29(2-3):250-264.
13. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. Behav Brain Res 1988, 31:47-59.
14. Filiou M.D., Teplytska L., Otte D.M., Zimmer A., Turck C.W. Myelination and oxidative stress alterations in the cerebellum of the G72/G30 transgenic schizophrenia mouse model. J Psychiatr Res 2012, 46:1359-1365.
15. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011, 14:123-130.
16. Glantz L.A., Lewis D.A. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000, 57:65-73.
17. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr Bull 2000, 26:119-136.
18. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004, 65:361-372.
19. Hashimoto K., Fujita Y., Shimizu E., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur J Pharmacol 2005, 519:114-117.
20. Horváth Z.C., Czopf J., Buzsáki G. MK-801-induced neuronal damage in rats. Brain Res 1997, 753:181-195.
21. Hou Y., Wu C.F., Yang J.Y., Guo T. Differential effects of haloperidol, clozapine and olanzapine on learning and memory functions in mice. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1486-1495.
22. Jacobs P.S., Taylor B.M., Bardgett M.E. Maturation of locomotor and Fos responses to the NMDA antagonists, PCP and MK-801. Brain Res Dev Brain Res 2000, 122:91-95.
23. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991, 148:1301-1308.
24. Józwiak L., Lukawski K., Sieklucka-Dziuba M. Cerebral oligemic hypoxia and MK-801 treatment: effect on alternation behavior in mice. Pharmacol Rep 2006, 58:770-773.
25. Juckel G., Manitz M.P., Brüne M., Friebe A., Heneka M.T., Wolf R.J. Microglial activation in a neuroinflammational animal model of schizophrenia-a pilot study. Schizophr Res 2011, 131:96-100.
26. Kos T., Nikiforuk A., Rafa D., Popik P. The effects of NMDA receptor antagonists on attentional set-shifting task performance in mice. Psychopharmacology (Berl) 2011, 214:911-921.
27. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199-214.
28. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003, 169:215-233.
29. Kunitachi S., Fujita Y., Ishima T., Kohno M., Horio M., Tanibuchi Y., et al. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors. Brain Res 2009, 1279:189-196.
30. Li H.C., Chen Q.Z., Ma Y., Zhou J.F. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejiang Univ Sci B 2006, 7:981-986.
31. Li Z., Boules M., Williams K., Gordillo A., Li S., Richelson E. Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia. Neurobiol Dis 2010, 40:467-477.
32. Monji A., Kato T., Kanba S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009, 63:257-265.
33. Nikiforuk A., Golembiowska K., Popik P. Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats. Eur Neuropsychopharmacol 2010, 20:37-48.
34. Nilsson M., Hansson S., Carlsson A., Carlsson M.L. Differential effects of the N-methyl-d-Aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice. Neuroscience 2007, 149:123-130.
35. Noda Y., Yamada K., Furukawa H., Nabeshima T. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 1995, 116:2531-2537.
36. Noda Y., Mamiya T., Furukawa H., Nabeshima T. Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 1997, 324:135-140.
37. Noda Y., Kamei H., Mamiya T., Furukawa H., Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 2000, 23:375-387.
38. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004, 72:29-39.
39. O'Donnell P. Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur J Neurosci 2012, 35:1866-1870.
40. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995, 52:998-1007.
41. Pearlson G.D. Neurobiology of schizophrenia. Ann Neurol 2000, 48:556-566.
42. Pitsikas N., Boultadakis A., Sakellaridis N. Effects of sub-anesthetic doses of ketamine on rats' spatial and non-spatial recognition memory. Neuroscience 2008, 154:454-460.
43. Radonjić N.V., Knezević I.D., Vilimanovich U., Kravić-Stevović T., Marina L.V., Nikolić T., et al. Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Neuropharmacology 2010, 58:739-745.
44. Ransohoff R.M., Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009, 27:119-145.
45. Rao V.S., Carvalho A.C., Trevisan M.T., Andrade G.M., Nobre-Júnior H.V., Moraes M.O., et al. Mangiferin ameliorates 6-hydroxydopamine-induced cytotoxicity and oxidative stress in ketamine model of schizophrenia. Pharmacol Rep 2012, 64:848-856.
46. Reus V.I. Mental disorders. Harrison's principles of internal medicine 2008, 2710-2723. McGraw-Hill, New York. A.S. Fauci, E. Braunwald, D.L. Kasper, S.L. Hauser, D.L. Longo, J.L. Jameson, J. Loscalzo (Eds.).
47. Sams-Dodd F. Effects of continuous d-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998, 19:18-25.
48. Sarter M., Bodewitz G., Stephens D.N. Attenuation of scopolamine-induced impairment of spontaneous alternation behavior by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology 1988, 94:491-495.
49. Saykin A.J., Gur R.C., Gur R.E., Mozley P.D., Mozley L.H., Resnick S.M. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991, 48:618-624.
50. Steiner J., Mawrin C., Ziegeler A., Bielau H., Ullrich O., Bernstein H.G., et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006, 112:305-316.
51. Stojković T., Radonjić N.V., Velimirović M., Jevtić G., Popović V., Doknić M., et al. Risperidone reverses phencyclidine induced decrease in glutathione levels and alterations of antioxidant defense in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:192-199.
52. Sullivan E.M., O'Donnell P. Inhibitory interneurons, oxidative stress, and schizophrenia. Schizophr Bull 2012, 38:373-376.
53. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 2002, 42:165-179.
54. van Berckel B.N., Bossong M.G., Boellaard R., Kloet R., Schuitemaker A., Caspers E., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008, 64:820-822.
55. Wierzba-Bobrowicz T., Lewandowska E., Lechowicz W., Stepień T., Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 2005, 43:81-89.
56. Wu J.Q., Kosten T.R., Zhang X.Y. Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry Mar 4 2013, [doi:pii: S0278-5846(13)00049-3. [Epub ahead of print]]. 10.1016/j.pnpbp.2013.02.015.
57. Yao J.K., Keshavan M.S. Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011, 15:2011-2035.
58. Zhao Y.N., Wang F., Fan Y.X., Ping G.F., Yang J.Y., Wu C.F. Activated microglia are implicated in cognitive deficits, neuronal death, and successful recovery following intermittent ethanol exposure. Behav Brain Res 2013, 236:270-282.
59. Zuo D.Y., Zhang Y.H., Cao Y., Wu C.F., Tanaka M., Wu Y.L. Effect of acute and chronic MK-801 administration on extracellular glutamate and ascorbic acid release in the prefrontal cortex of freely moving mice on line with open-field behavior. Life Sci 2006, 78:2172-2178.